<h4>Background</h4>Despite intravitreal anti-vascular endothelial growth factor (VEGF) therapy being the standard of care for neovascular age-related macular degeneration (nAMD), long-term visual decline remains common, with subretinal fibrosis representing a major cause of irreversible vision loss. The gene discussed is VEGFA; the disease is wet macular degeneration.